Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving management of intravenous maintenance fluids in the emergency department of a university hospital.

European review for medical and pharmacological sciences·2024
Same author

Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients?

European journal of clinical pharmacology·2016
Same author

Relationship between pre-stroke cardiovascular medication use and stroke severity.

European journal of clinical pharmacology·2015
Same author

Comparison of two approaches of INR-follow-up and determinants of INR-stability.

Acta clinica Belgica·2015
Same author

Pharmacists' role in handling problems with prescriptions for antithrombotic medication in Belgian community pharmacies.

International journal of clinical pharmacy·2015
Same author

Physician's expectations regarding prescribing clinical decision support systems in a Belgian hospital.

Acta clinica Belgica·2014
Same journal

MEFV variants as phenotypic modifiers in ankylosing spondylitis: a genetic interaction analysis with HLA-B27.

Acta clinica Belgica·2026
Same journal

What Europe should (not) learn from the new Dietary Guidelines for Americans.

Acta clinica Belgica·2026
Same journal

Real-world evidence on In-hospital statin use and mortality in geriatric patients.

Acta clinica Belgica·2026
Same journal

TKI-associated proteinuria and nephrotic syndrome: a narrative review with clinical illustration in radio-iodine-refractory thyroid cancer.

Acta clinica Belgica·2026
Same journal

A decade of insulin pump therapy in a Belgian paediatric diabetes centre: longitudinal outcomes and evolving practices.

Acta clinica Belgica·2026
Same journal

Pneumococcal vaccination in Belgian adults: a practical translation of the 2025 Superior Health Council guidelines.

Acta clinica Belgica·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

Generics: need for clinical concern?

F R Heller1, A G Dupont

  • 1Département de Médecine Interne, Centre Hospitalier Jolimont-Lobbes, Haine St Paul, Belgique. heller.cs.jolimont@skynet.be

Acta Clinica Belgica
|December 17, 2009
PubMed
Summary
This summary is machine-generated.

Generic drugs, while cost-effective, may pose risks due to variable efficacy and side effects, especially for critical conditions like epilepsy. Ensuring pharmaceutical quality is crucial for patient safety and therapeutic equivalence.

Related Experiment Videos

Last Updated: Jun 17, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

Area of Science:

  • Pharmacology
  • Pharmaceutical Sciences
  • Drug Safety

Background:

  • The global generic drug market is expanding, driven by lower costs.
  • Generic substitution is increasingly common in Western and developed countries.
  • Clinical concerns regarding generic drug efficacy and safety have emerged.

Purpose of the Study:

  • To investigate the clinical implications of generic drug substitution.
  • To evaluate potential differences in efficacy and side-effect profiles between generic and originator drugs.
  • To highlight concerns related to pharmaceutical quality and therapeutic equivalence.

Main Methods:

  • Review of existing studies on generic drug substitution.
  • Analysis of pharmacokinetic and pharmacodynamic data.
  • Assessment of therapeutic outcomes in specific patient populations.

Main Results:

  • Generic substitution may be linked to reduced drug efficacy or increased adverse events.
  • Concerns are particularly relevant for severe conditions like epilepsy and cardiac arrhythmia.
  • Therapeutic bioequivalence based on pharmacokinetics does not guarantee identical clinical activity, especially for narrow therapeutic index drugs.
  • Lower pharmaceutical quality, often linked to specific manufacturing countries, raises safety concerns.

Conclusions:

  • Switching between generic and originator drugs can be problematic, particularly for patients with narrow therapeutic index medications.
  • The assumption of therapeutic equivalence based solely on bioavailability may be insufficient.
  • Stricter quality control in generic drug manufacturing is essential to ensure patient safety and consistent therapeutic outcomes.